>TOP >Our business >Evec's Products for Licensing

Evec's Products for Licensing

Clostridium difficile

  • Gram-positive, spore-forming, anaerobic bacterium
  • Leading cause of hospital-acquired diarrhea in developed countries
  • C. Difficile infection (CDI) affects approximately 500,000 individuals and causes more than 20,000 deaths and more than $1 billion in healthcare costs annually in the United States
  • Current antibiotic therapy is associated with incomplete response or disease recurrence in approximately 30% of patients
  • Main virulence factors are toxin A and toxin B

1.Evec's Abs against Clostridium difficile EV029105a, mAb against toxin A EV029104, mAb against toxin B

  • Human mAbs for prevention and treatment of C. Difficile infection
  • Fully human mAbs derived from human B-lymphocytes
  • IgG1 Abs
  • Demonstrated efficacy in vitro and in animal model of C. Difficile infection

2.In vitro neutralization activities of anti-toxin A Abs

IMR-90 cells were added to 96-well plates at 3.5 ×104 cells per well. Toxin A (20 ng/ml) was combined with serially diluted mAbs for 1hour at 37C and then added to the cells. After incubation for 24 hours, percentages of rounding cells were determined.

3.Effects of anti-C. difficile Abs in a hamster model of C. difficile infection

Human Metapneumovirus (hMPV)

  • Family Paramyxoviridae, Subfamily Pneumovirinae
  • Related genetically to respiratory syncytial virus (RSV)
  • Two serotypes were identified, each of which represents 2 lineages (A1, A2, B1, and B2, respectively), which are also reflected by genetic diversity of the virus
  • About 10% of children hospitalized with acute respiratory tract infections suffer from MPV infection
  • A major cause of severe and sometimes even fatal respiratory infections in immunocompromised patients
  • Fusion (F) protein is the most important target of protective immunity

1.Evec's Abs against hMPV

  • Human mAbs for prevention and treatment of hMPV infection
  • 13 independent fully human mAbs derived from human B-lymphocytes
  • IgG1 Abs
  • Demonstrated efficacy in vitro

2.In vitro neutralization of MPV infection

High mobility group box 1 (HMGB1)

  • A ubiquitous nuclear protein
  • Released from cells during innate immune response, apoptosis and necrosis
  • Sepsis
    • HMGB1 acts as a cytokine that mediates organ damage in sepsis
      Sepsis is systemic inflammation caused by infections. In the United States, sepsis is the third leading cause of death and accounts for 9% of all deaths
  • Neuropathic pain
    • HMGB1 is released after nerve injury and contributes to the development of neuropathic pain

1.Evec's Ab against HMGB1 EV007156

  • Humanized mAb
  • IgG1, λ
  • Binds HMGB1, but not HMGB2
  • Binds all types of HMGB1
  • Inhibits HMGB1 binding to RAGE
  • Effective in animal disease models of sepsis

2.Reactivity of anti-HMGB1 antibodies with HMGB1

S6 and G4 are anti-HMGB1 human Abs from Medimmune, and were produced by Evec, Inc. for direct comparison

3.Inhibition of HMGB1 binding to RAGE-Fc by anti-HMGB1 Abs

S6 G4
IC50 (μg/ml) 0.12 0.17 14.47 3.56

4.Effects of Evec's anti-HMGB1 mAb on Sepsis  (caecal ligation and puncture model in mice)

5.Effects of Evec's anti-HMGB1 mAb on partial sciatic nerve ligation (PSNL) in rats

  • We are seeking Alliance partners
  • Inquiries by the media and press
  • Contract services. click here
  • EVEC, Inc.
    Taijuseimei-Odori Bldg 8F,
    Odori W6,Chuo-ku,Sapporo
    Postal code 060-0042
    Email info@evec.jp
  • Minister Award for Science, Technology and Innovation Policy of Japan